Background & Aims Nivolumab, an immune checkpoint inhibitor, is approved in several
countries to treat sorafenib-experienced patients with HCC, based on results from the …

Background For patients with advanced hepatocellular carcinoma, sorafenib is the only
approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and …

Background Single-agent nivolumab showed durable responses, manageable safety, and
promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2 …

Importance Most patients with hepatocellular carcinoma (HCC) are diagnosed with advanced
disease not eligible for potentially curative therapies; therefore, new treatment options are …

Background In the international randomised phase 3 CORRECT trial (NCT01103323),
regorafenib significantly improved overall survival versus placebo in patients with treatment-…

Background & Aims We aimed to develop a prognostic classification scheme with treatment
guidance for Asian patients with hepatocellular carcinoma (HCC). Methods We collected …

Dear Editor, Coronavirus disease 2019 (COVID-19) caused by the novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 has resulted in over 13 million confirmed …

Background A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated
antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion …

PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II
KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). …

Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of care …